CRBU
Caribou Biosciences, Inc.
Price Chart
Latest Quote
$1.64
+0.00 (+0.00%)
Current Price
| Previous Close | $1.64 |
| Open | $1.67 |
| Day High | $1.69 |
| Day Low | $1.57 |
| Volume | 2,516,681 |
Stock Information
| Shares Outstanding | 99.18M |
| Total Debt | $26.95M |
| Cash Equivalents | $117.63M |
| Revenue | $11.20M |
| Net Income | $-133.22M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $162.66M |
| EPS (TTM) | $-1.42 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $71.98M |
| Sales | $11.20M |
| Income | $-133.22M |
| Book/sh | $1.05 |
| Cash/sh | $1.19 |
| Employees | 97 |
Financial Ratios
| Quick Ratio | 6.10 |
| Current Ratio | 6.22 |
| Debt/Eq | 26.41 |
Returns & Margins
| ROA | -34.69% |
| ROE | -83.46% |
| Operating Margin | -1096.37% |
Ownership
| Insider Ownership | 8.91% |
| Institutional Ownership | 37.75% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.17 |
| P/S | 14.52 |
| P/B | 1.56 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $12.00 |
Technical Indicators
| SMA20 | $1.97 |
| SMA50 | $2.02 |
| SMA200 | $1.94 |
| RSI | 19.49 |
| ATR | 0.1586 |
| Shares Float | 94.81M |
| Short Float | 7.82% |
| Short Ratio | 4.45 |
| Volatility | 2.33 |
| Rel Volume | 1.34 |
Performance History
| Week | -1.20% |
| Month | -16.75% |
| Quarter | -16.75% |
| 6 Months | -2.96% |
| YTD | +3.14% |
| Year | +41.38% |
| 3 Years | -66.46% |
| 10 Years | -89.95% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.64 | 2,539,700 |
| 2026-06-17 | $1.64 | 1,737,000 |
| 2026-06-16 | $1.69 | 2,087,800 |
| 2026-06-15 | $1.66 | 1,707,600 |
| 2026-06-12 | $1.60 | 2,293,100 |
| 2026-06-11 | $1.66 | 2,704,800 |
| 2026-06-10 | $1.79 | 967,800 |
| 2026-06-09 | $1.84 | 1,632,200 |
| 2026-06-08 | $1.84 | 1,656,000 |
| 2026-06-05 | $1.92 | 1,677,200 |
| 2026-06-04 | $2.07 | 1,745,500 |
| 2026-06-03 | $2.00 | 2,141,700 |
| 2026-06-02 | $2.32 | 1,738,300 |
| 2026-06-01 | $2.43 | 1,966,700 |
| 2026-05-29 | $2.36 | 1,389,400 |
| 2026-05-28 | $2.31 | 1,539,500 |
| 2026-05-27 | $2.31 | 3,736,000 |
| 2026-05-26 | $2.16 | 1,938,400 |
| 2026-05-22 | $2.10 | 1,394,300 |
| 2026-05-21 | $1.99 | 1,368,300 |
| 2026-05-20 | $2.00 | 1,709,800 |
| 2026-05-19 | $1.97 | 1,801,700 |
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
đ° Latest News
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
MarketBeat âĸ 2026-06-09T10:04:51Z
Caribou Biosciences (CRBU) Gets A Higher Target As Confidence In Its Pipeline Grows
Insider Monkey âĸ 2026-05-31T14:38:29Z
May 2026's Promising Penny Stocks
Simply Wall St. âĸ 2026-05-14T12:04:54Z
Industry Analysts Just Made A Massive Upgrade To Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenue Forecasts
Simply Wall St. âĸ 2026-05-13T12:07:52Z
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-07T23:05:24Z
Discovering Whitehawk Therapeutics Among 3 Promising Penny Stocks
Simply Wall St. âĸ 2026-04-15T12:05:27Z
Three Best Genomics Stocks for Your Portfolio in 2026
Zacks âĸ 2026-04-13T14:19:00Z
Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-04-02T13:03:00Z
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-03-26T12:57:00Z
Is CareCloud (CCLD) Outperforming Other Medical Stocks This Year?
Zacks âĸ 2026-03-16T13:40:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $11,159,000 | $9,994,000 | $34,477,000 | $13,851,000 |
| Operating Revenue | $11,159,000 | $9,994,000 | $34,477,000 | $13,851,000 |
| Expenses | ||||
| Total Expenses | $147,353,000 | $176,610,000 | $150,536,000 | $120,250,000 |
| Other Income Expense | $-12,481,000 | $17,502,000 | $14,182,000 | $7,048,000 |
| Other Non Operating Income Expenses | $8,827,000 | $17,502,000 | $14,182,000 | $7,181,000 |
| Operating Expense | $147,353,000 | $176,610,000 | $150,536,000 | $120,250,000 |
| General And Administrative Expense | $37,914,000 | $46,457,000 | $38,461,000 | $38,020,000 |
| Interest Expense | - | - | - | - |
| Net Non Operating Interest Income Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-148,125,000 | $-149,105,000 | $-102,070,000 | $-99,421,000 |
| Normalized Income | $-126,902,232 | $-149,105,000 | $-102,070,000 | $-99,315,930 |
| Net Income From Continuing And Discontinued Operation | $-148,125,000 | $-149,105,000 | $-102,070,000 | $-99,421,000 |
| Total Operating Income As Reported | $-148,344,000 | $-166,616,000 | $-116,059,000 | $-106,399,000 |
| Net Income Common Stockholders | $-148,125,000 | $-149,105,000 | $-102,070,000 | $-99,421,000 |
| Net Income | $-148,125,000 | $-149,105,000 | $-102,070,000 | $-99,421,000 |
| Net Income Including Noncontrolling Interests | $-148,125,000 | $-149,105,000 | $-102,070,000 | $-99,421,000 |
| Net Income Continuous Operations | $-148,125,000 | $-149,105,000 | $-102,070,000 | $-99,421,000 |
| Pretax Income | $-148,675,000 | $-149,114,000 | $-101,877,000 | $-99,351,000 |
| Special Income Charges | $-21,308,000 | $0 | - | $0 |
| Operating Income | $-136,194,000 | $-166,616,000 | $-116,059,000 | $-106,399,000 |
| Net Interest Income | - | - | - | - |
| Interest Income | - | - | - | - |
| Interest Income Non Operating | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-1.59 | $-1.65 | $-1.38 | $-1.64 |
| Basic EPS | $-1.59 | $-1.65 | $-1.38 | $-1.64 |
| Other | ||||
| Tax Effect Of Unusual Items | $-85,232 | $0 | $0 | $-27,930 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-111,241,000 | $-162,689,000 | $-112,534,000 | $-104,644,000 |
| Total Unusual Items | $-21,308,000 | $0 | $-6,000 | $-133,000 |
| Total Unusual Items Excluding Goodwill | $-21,308,000 | $0 | $-6,000 | $-133,000 |
| Reconciled Depreciation | $3,645,000 | $3,927,000 | $3,525,000 | $1,622,000 |
| EBITDA (Bullshit earnings) | $-132,549,000 | $-162,689,000 | $-112,534,000 | $-104,777,000 |
| EBIT | $-136,194,000 | $-166,616,000 | $-116,059,000 | $-106,399,000 |
| Diluted Average Shares | $93,389,283 | $90,317,925 | $73,807,597 | $60,801,133 |
| Basic Average Shares | $93,389,283 | $90,317,925 | $73,807,597 | $60,801,133 |
| Diluted NI Availto Com Stockholders | $-148,125,000 | $-149,105,000 | $-102,070,000 | $-99,421,000 |
| Tax Provision | $-550,000 | $-9,000 | $193,000 | $70,000 |
| Write Off | $21,308,000 | $0 | - | - |
| Research And Development | $109,439,000 | $130,153,000 | $112,075,000 | $82,230,000 |
| Selling General And Administration | $37,914,000 | $46,457,000 | $38,461,000 | $38,020,000 |
| Other Gand A | $37,914,000 | $46,457,000 | $38,461,000 | $38,020,000 |
| Gain On Sale Of Security | - | - | $-6,000 | $-133,000 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $122,175,000 | $252,951,000 | $368,401,000 | $300,871,000 |
| Total Assets | $175,367,000 | $313,313,000 | $432,209,000 | $373,765,000 |
| Total Non Current Assets | $30,135,000 | $93,936,000 | $93,368,000 | $113,517,000 |
| Other Non Current Assets | $2,200,000 | $5,521,000 | $1,586,000 | $1,538,000 |
| Investmentin Financial Assets | $3,505,000 | $49,125,000 | $51,330,000 | $77,071,000 |
| Current Assets | $145,232,000 | $219,377,000 | $338,841,000 | $260,248,000 |
| Prepaid Assets | $2,913,000 | $6,589,000 | $4,935,000 | $6,802,000 |
| Receivables | $2,979,000 | $3,251,000 | $3,859,000 | $4,664,000 |
| Other Receivables | $2,910,000 | $2,986,000 | $3,009,000 | $3,892,000 |
| Accounts Receivable | $69,000 | $265,000 | $148,000 | $202,000 |
| Cash Cash Equivalents And Short Term Investments | $139,340,000 | $209,537,000 | $328,827,000 | $247,663,000 |
| Cash And Cash Equivalents | $12,360,000 | $16,293,000 | $51,162,000 | $58,338,000 |
| Cash Equivalents | $12,360,000 | $16,293,000 | $51,162,000 | $58,338,000 |
| Other Current Assets | - | $1,781,000 | $1,220,000 | $1,119,000 |
| Accrued Interest Receivable | - | $930,000 | $702,000 | $570,000 |
| Debt | ||||
| Total Debt | $27,227,000 | $26,487,000 | $27,108,000 | $27,746,000 |
| Long Term Debt And Capital Lease Obligation | $26,026,000 | $25,061,000 | $25,908,000 | $26,780,000 |
| Current Debt And Capital Lease Obligation | $1,201,000 | $1,426,000 | $1,200,000 | $966,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $53,192,000 | $60,362,000 | $63,808,000 | $72,894,000 |
| Total Non Current Liabilities Net Minority Interest | $27,778,000 | $29,711,000 | $35,506,000 | $44,766,000 |
| Non Current Deferred Liabilities | $1,752,000 | $3,865,000 | $6,659,000 | $16,335,000 |
| Non Current Deferred Taxes Liabilities | $0 | $548,000 | $557,000 | $381,000 |
| Current Liabilities | $25,414,000 | $30,651,000 | $28,302,000 | $28,128,000 |
| Other Current Liabilities | $816,000 | $1,679,000 | $1,106,000 | $1,370,000 |
| Current Deferred Liabilities | $1,895,000 | $3,129,000 | $2,847,000 | $9,937,000 |
| Payables And Accrued Expenses | $13,757,000 | $15,857,000 | $13,632,000 | $10,103,000 |
| Payables | $5,783,000 | $2,476,000 | $3,120,000 | $1,146,000 |
| Accounts Payable | $5,783,000 | $2,476,000 | $3,120,000 | $1,146,000 |
| Other Non Current Liabilities | - | $785,000 | $2,939,000 | $1,651,000 |
| Equity | ||||
| Common Stock Equity | $122,175,000 | $252,951,000 | $368,401,000 | $300,871,000 |
| Total Equity Gross Minority Interest | $122,175,000 | $252,951,000 | $368,401,000 | $300,871,000 |
| Stockholders Equity | $122,175,000 | $252,951,000 | $368,401,000 | $300,871,000 |
| Gains Losses Not Affecting Retained Earnings | $103,000 | $255,000 | $30,000 | $-1,518,000 |
| Retained Earnings | $-596,515,000 | $-448,390,000 | $-299,285,000 | $-197,215,000 |
| Other | ||||
| Ordinary Shares Number | $95,143,690 | $92,378,577 | $88,448,948 | $61,029,184 |
| Share Issued | $95,143,690 | $92,378,577 | $88,448,948 | $61,029,184 |
| Tangible Book Value | $122,175,000 | $252,951,000 | $368,401,000 | $300,871,000 |
| Invested Capital | $122,175,000 | $252,951,000 | $368,401,000 | $300,871,000 |
| Working Capital | $119,818,000 | $188,726,000 | $310,539,000 | $232,120,000 |
| Capital Lease Obligations | $27,227,000 | $26,487,000 | $27,108,000 | $27,746,000 |
| Total Capitalization | $122,175,000 | $252,951,000 | $368,401,000 | $300,871,000 |
| Additional Paid In Capital | $718,578,000 | $701,077,000 | $667,648,000 | $499,598,000 |
| Capital Stock | $9,000 | $9,000 | $8,000 | $6,000 |
| Common Stock | $9,000 | $9,000 | $8,000 | $6,000 |
| Non Current Deferred Revenue | $1,752,000 | $3,317,000 | $6,102,000 | $15,954,000 |
| Long Term Capital Lease Obligation | $26,026,000 | $25,061,000 | $25,908,000 | $26,780,000 |
| Current Deferred Revenue | $1,895,000 | $3,129,000 | $2,847,000 | $9,937,000 |
| Current Capital Lease Obligation | $1,201,000 | $1,426,000 | $1,200,000 | $966,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,745,000 | $8,560,000 | $9,517,000 | $5,752,000 |
| Current Accrued Expenses | $7,974,000 | $13,381,000 | $10,512,000 | $8,957,000 |
| Investments And Advances | $3,505,000 | $49,125,000 | $51,330,000 | $77,071,000 |
| Available For Sale Securities | $3,505,000 | $49,125,000 | $51,330,000 | $77,071,000 |
| Net PPE | $24,430,000 | $39,290,000 | $40,452,000 | $34,908,000 |
| Accumulated Depreciation | $-13,527,000 | $-12,885,000 | $-9,144,000 | $-5,649,000 |
| Gross PPE | $37,957,000 | $52,175,000 | $49,596,000 | $40,557,000 |
| Leases | $3,057,000 | $11,518,000 | $2,235,000 | $1,876,000 |
| Other Properties | $33,306,000 | $39,063,000 | $37,763,000 | $36,818,000 |
| Machinery Furniture Equipment | $1,594,000 | $1,594,000 | $1,394,000 | $870,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $126,980,000 | $193,244,000 | $277,665,000 | $189,325,000 |
| Construction In Progress | - | $0 | $8,204,000 | $993,000 |
| Preferred Stock | - | - | - | $0 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-112,351,000 | $-144,705,000 | $-104,904,000 | $-98,020,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-110,992,000 | $-138,200,000 | $-93,291,000 | $-90,966,000 |
| Cash Flow From Continuing Operating Activities | $-110,992,000 | $-138,200,000 | $-93,291,000 | $-90,966,000 |
| Operating Gains Losses | $-25,000 | $-9,000 | $-34,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,359,000 | $-6,505,000 | $-11,613,000 | $-7,054,000 |
| Investing Cash Flow | $102,238,000 | $86,607,000 | $-68,183,000 | $-93,249,000 |
| Cash Flow From Continuing Investing Activities | $102,238,000 | $86,607,000 | $-68,183,000 | $-93,249,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $4,070,000 | $15,192,000 | $152,720,000 | $0 |
| Financing Cash Flow | $4,821,000 | $16,724,000 | $154,298,000 | $2,133,000 |
| Cash Flow From Continuing Financing Activities | $4,821,000 | $16,724,000 | $154,298,000 | $2,133,000 |
| Net Common Stock Issuance | $4,070,000 | $15,192,000 | $152,720,000 | $0 |
| Common Stock Issuance | $4,070,000 | $15,192,000 | $152,720,000 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $12,406,000 | $16,339,000 | $51,208,000 | $58,384,000 |
| Beginning Cash Position | $16,339,000 | $51,208,000 | $58,384,000 | $240,466,000 |
| Changes In Cash | $-3,933,000 | $-34,869,000 | $-7,176,000 | $-182,082,000 |
| Proceeds From Stock Option Exercised | $751,000 | $1,532,000 | $1,578,000 | $2,133,000 |
| Net Investment Purchase And Sale | $103,597,000 | $93,099,000 | $-56,570,000 | $-86,195,000 |
| Sale Of Investment | $252,830,000 | $397,492,000 | $338,188,000 | $252,868,000 |
| Purchase Of Investment | $-149,233,000 | $-304,393,000 | $-394,758,000 | $-339,063,000 |
| Net Intangibles Purchase And Sale | $0 | $-1,625,000 | $0 | $-600,000 |
| Purchase Of Intangibles | $0 | $-1,625,000 | $0 | $-600,000 |
| Net PPE Purchase And Sale | $-1,359,000 | $-4,867,000 | $-11,613,000 | $-6,454,000 |
| Sale Of PPE | $0 | $13,000 | $0 | - |
| Purchase Of PPE | $-1,359,000 | $-4,880,000 | $-11,613,000 | $-6,454,000 |
| Change In Working Capital | $-484,000 | $-5,114,000 | $-7,318,000 | $-4,204,000 |
| Change In Other Working Capital | $-3,346,000 | $-2,513,000 | $-16,766,000 | $-4,939,000 |
| Change In Other Current Liabilities | $-1,349,000 | $-621,000 | $-637,000 | $-418,000 |
| Change In Other Current Assets | $3,350,000 | $-3,935,000 | $-48,000 | $-564,000 |
| Change In Payables And Accrued Expense | $-3,086,000 | $1,780,000 | $7,562,000 | $-768,000 |
| Change In Accrued Expense | $-6,340,000 | $2,134,000 | $5,743,000 | $1,953,000 |
| Change In Payable | $3,254,000 | $-354,000 | $1,819,000 | $-2,721,000 |
| Change In Account Payable | $3,254,000 | $-354,000 | $1,819,000 | $-2,721,000 |
| Change In Prepaid Assets | $3,675,000 | $-433,000 | $1,766,000 | $-975,000 |
| Change In Receivables | $272,000 | $608,000 | $805,000 | $3,460,000 |
| Changes In Account Receivables | $196,000 | $-117,000 | $54,000 | $951,000 |
| Other Non Cash Items | $1,050,000 | $10,000 | $3,275,000 | $-15,000 |
| Stock Based Compensation | $12,680,000 | $16,706,000 | $13,750,000 | $11,716,000 |
| Unrealized Gain Loss On Investment Securities | $99,000 | $111,000 | $6,000 | $133,000 |
| Asset Impairment Charge | $21,308,000 | $0 | - | - |
| Amortization Of Securities | $-1,140,000 | $-4,726,000 | $-4,425,000 | $-797,000 |
| Depreciation Amortization Depletion | $3,645,000 | $3,927,000 | $3,525,000 | $1,622,000 |
| Depreciation And Amortization | $3,645,000 | $3,927,000 | $3,525,000 | $1,622,000 |
| Depreciation | $3,645,000 | $3,927,000 | - | - |
| Gain Loss On Sale Of PPE | $-25,000 | $-9,000 | $-34,000 | $0 |
| Net Income From Continuing Operations | $-148,125,000 | $-149,105,000 | $-102,070,000 | $-99,421,000 |
| Income Tax Paid Supplemental Data | - | $0 | $170,000 | $0 |
| Repayment Of Debt | - | - | - | $0 |
| Issuance Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-06-19